Fondazione Policlinico Gemelli IRCCS Trials

Fondazione Policlinico Gemelli IRCCS	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Piperno-Neumann, Sophie

TANGENT, NCT05417789: Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

Recruiting

128

Europe, Canada, US, RoW

Emactuzumab, Placebo

SynOx Therapeutics Limited

TGCT

04/26

09/27

DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma

Recruiting

2/3

420

Europe, Canada, US, RoW

IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome

IDEAYA Biosciences

Metastatic Uveal Melanoma

01/27

01/28

IDE196-009, NCT05907954: (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Recruiting

Europe, Canada, US, RoW

Darovasertib, IDE196, LXS196

IDEAYA Biosciences

Uveal Melanoma

01/26

01/29

CAMPFIRE, NCT05999994: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Recruiting

105

Europe, Japan, US, RoW

Ramucirumab, LY3009806, Cyclophosphamide, Vinorelbine, Gemcitabine, LY188011, Docetaxel, Abemaciclib, LY2835219, Irinotecan, Temozolomide

Eli Lilly and Company

Neoplasms, Child, Adolescent

05/27

NCT04879017: FHD-286 in Subjects With Metastatic Uveal Melanoma

Terminated

Europe, US

FHD-286

Foghorn Therapeutics Inc.

Metastatic Uveal Melanoma

11/23

Jamal, Rahima

DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma

Recruiting

2/3

420

Europe, Canada, US, RoW

IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome

IDEAYA Biosciences

Metastatic Uveal Melanoma

01/27

01/28

NCT04836195: Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma

Completed

Canada

PCLX-001 - 20mg, zelenirstat, PCLX-001 - 40mg, PCLX-001 - 70mg, PCLX-001 - 100mg, PCLX-001 - 140mg, PCLX-001 - 210mg, PCLX-001 - 280mg

Pacylex Pharmaceuticals, Ozmosis Research Inc.

B-cell Non Hodgkin Lymphoma, Advanced Solid Tumor

10/24

Neidhardt, Eve-Marie

DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma

Recruiting

2/3

420

Europe, Canada, US, RoW

IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome

IDEAYA Biosciences

Metastatic Uveal Melanoma

01/27

01/28

Walker, John R

DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma

Recruiting

2/3

420

Europe, Canada, US, RoW

IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome

IDEAYA Biosciences

Metastatic Uveal Melanoma

01/27

01/28

LATENT, NCT03357757: Avelumab With Valproic Acid in Virus-associated Cancer

Active, not recruiting

Canada

Valproic Acid, Avelumab

AHS Cancer Control Alberta, EMD Serono

Cancer That is Associated With a Chronic Viral Infection, p16 Positive SCCHN, Squamous Cell Carcinoma of the Cervix, p16 Positive Squamous Cell Carcinoma of the Vagina or Vulva, p16 Positive Squamous Cell Carcinoma of the Penis, p16 Positive Squamous Cell Carcinoma of the Anus or Anal Canal, EBER Positive NPC, EBER Positive Hodgkins and Non-hodgkins Lymphona

03/22

02/27

UNSCARRed, NCT03737721: The Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy

Active, not recruiting

Canada

Avelumab and Radical radiotherapy

AHS Cancer Control Alberta, EMD Serono, Alberta Cancer Foundation

Squamous Cell Carcinoma of the Skin

11/22

12/24

Scambia, Giovanni

NCT02584478 / 2021-003871-32: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

Active, not recruiting

294

Europe, US, RoW

AL3818, Anlotinib Hydrochloride, Anlotinib, Catequentinib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Daily Topotecan, Weekly Topotecan, Carboplatin, Paraplatin, Taxol

Advenchen Laboratories, LLC, Advenchen Laboratories, LLC

Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma

10/24

12/24

FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting

615

Europe, Canada, US, RoW

Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo

CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms

09/25

08/27

PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting

1/2

230

Europe, US, RoW

rezatapopt, PC14586, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79

PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC

Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer

03/26

07/26

Baurain, Jean Francois

DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma

Recruiting

2/3

420

Europe, Canada, US, RoW

IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome

IDEAYA Biosciences

Metastatic Uveal Melanoma

01/27

01/28

NCT06433219: Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Recruiting

Europe, US, RoW

Tuvusertib (M1774), M1774, VXc-400, VRT-1363004, substance code MSC2584415A, Niraparib, GSK3985771, MK-4827, Lartesertib (M4076), M4076, substance code MSC2585823A

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Ovarian Cancer

01/28

Teofili, Luciana

BORN, NCT05100212: umBilical Or Adult Donor Red Blood Cells in Extremely Low Gestational Age Neonates and Retinopathy of Prematurity

Completed

146

Europe

cord blood-RBC concentrates, cord blood packed RBC, adult donor RBC concentrates, adult donor packed RBC

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Fresenius Kabi

Retinopathy of Prematurity

01/25

graziani, francesca

ICAR, NCT06894290: International Cardiac Amyloidosis Registry

Recruiting

N/A

300

Europe, Japan

Leiden University Medical Center, Pfizer

Cardiac Amyloidosis

07/26

McDowell, Rose

DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma

Recruiting

2/3

420

Europe, Canada, US, RoW

IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome

IDEAYA Biosciences

Metastatic Uveal Melanoma

01/27

01/28

Kalkavan, Halime

DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma

Recruiting

2/3

420

Europe, Canada, US, RoW

IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome

IDEAYA Biosciences

Metastatic Uveal Melanoma

01/27

01/28

Roberts-Thomson

DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma

Recruiting

2/3

420

Europe, Canada, US, RoW

IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome

IDEAYA Biosciences

Metastatic Uveal Melanoma

01/27

01/28

cammertoni, federico

No trials found

federico, cammertoni

No trials found

Maccauro, Giulio

No trials found

Vitiello, Raffaele

No trials found

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Piperno-Neumann, Sophie

TANGENT, NCT05417789: Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

Recruiting

128

Europe, Canada, US, RoW

Emactuzumab, Placebo

SynOx Therapeutics Limited

TGCT

04/26

09/27

DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma

Recruiting

2/3

420

Europe, Canada, US, RoW

IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome

IDEAYA Biosciences

Metastatic Uveal Melanoma

01/27

01/28

IDE196-009, NCT05907954: (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Recruiting

Europe, Canada, US, RoW

Darovasertib, IDE196, LXS196

IDEAYA Biosciences

Uveal Melanoma

01/26

01/29

CAMPFIRE, NCT05999994: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Recruiting

105

Europe, Japan, US, RoW

Ramucirumab, LY3009806, Cyclophosphamide, Vinorelbine, Gemcitabine, LY188011, Docetaxel, Abemaciclib, LY2835219, Irinotecan, Temozolomide

Eli Lilly and Company

Neoplasms, Child, Adolescent

05/27

NCT04879017: FHD-286 in Subjects With Metastatic Uveal Melanoma

Terminated

Europe, US

FHD-286

Foghorn Therapeutics Inc.

Metastatic Uveal Melanoma

11/23

Jamal, Rahima

DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma

Recruiting

2/3

420

Europe, Canada, US, RoW

IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome

IDEAYA Biosciences

Metastatic Uveal Melanoma

01/27

01/28

NCT04836195: Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma

Completed

Canada

PCLX-001 - 20mg, zelenirstat, PCLX-001 - 40mg, PCLX-001 - 70mg, PCLX-001 - 100mg, PCLX-001 - 140mg, PCLX-001 - 210mg, PCLX-001 - 280mg

Pacylex Pharmaceuticals, Ozmosis Research Inc.

B-cell Non Hodgkin Lymphoma, Advanced Solid Tumor

10/24

Neidhardt, Eve-Marie

DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma

Recruiting

2/3

420

Europe, Canada, US, RoW

IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome

IDEAYA Biosciences

Metastatic Uveal Melanoma

01/27

01/28

Walker, John R

DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma

Recruiting

2/3

420

Europe, Canada, US, RoW

IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome

IDEAYA Biosciences

Metastatic Uveal Melanoma

01/27

01/28

LATENT, NCT03357757: Avelumab With Valproic Acid in Virus-associated Cancer

Active, not recruiting

Canada

Valproic Acid, Avelumab

AHS Cancer Control Alberta, EMD Serono

03/22

02/27

UNSCARRed, NCT03737721: The Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy

Active, not recruiting

Canada

Avelumab and Radical radiotherapy

AHS Cancer Control Alberta, EMD Serono, Alberta Cancer Foundation

Squamous Cell Carcinoma of the Skin

11/22

12/24

Scambia, Giovanni

Active, not recruiting

294

Europe, US, RoW

AL3818, Anlotinib Hydrochloride, Anlotinib, Catequentinib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Daily Topotecan, Weekly Topotecan, Carboplatin, Paraplatin, Taxol

Advenchen Laboratories, LLC, Advenchen Laboratories, LLC

Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma

10/24

12/24

FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting

615

Europe, Canada, US, RoW

Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo

CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd

09/25

08/27

PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting

1/2

230

Europe, US, RoW

rezatapopt, PC14586, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79

PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC

03/26

07/26

Baurain, Jean Francois

DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma

Recruiting

2/3

420

Europe, Canada, US, RoW

IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome

IDEAYA Biosciences

Metastatic Uveal Melanoma

01/27

01/28

NCT06433219: Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Recruiting

Europe, US, RoW

Tuvusertib (M1774), M1774, VXc-400, VRT-1363004, substance code MSC2584415A, Niraparib, GSK3985771, MK-4827, Lartesertib (M4076), M4076, substance code MSC2585823A

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Ovarian Cancer

01/28

Teofili, Luciana

BORN, NCT05100212: umBilical Or Adult Donor Red Blood Cells in Extremely Low Gestational Age Neonates and Retinopathy of Prematurity

Completed

146

Europe

cord blood-RBC concentrates, cord blood packed RBC, adult donor RBC concentrates, adult donor packed RBC

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Fresenius Kabi

Retinopathy of Prematurity

01/25

graziani, francesca

ICAR, NCT06894290: International Cardiac Amyloidosis Registry

Recruiting

N/A

300

Europe, Japan

Leiden University Medical Center, Pfizer

Cardiac Amyloidosis

07/26

McDowell, Rose

DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma

Recruiting

2/3

420

Europe, Canada, US, RoW

IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome

IDEAYA Biosciences

Metastatic Uveal Melanoma

01/27

01/28

Kalkavan, Halime

DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma

Recruiting

2/3

420

Europe, Canada, US, RoW

IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome

IDEAYA Biosciences

Metastatic Uveal Melanoma

01/27

01/28

Roberts-Thomson

DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma

Recruiting

2/3

420

Europe, Canada, US, RoW

IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome

IDEAYA Biosciences

Metastatic Uveal Melanoma

01/27

01/28

cammertoni, federico

No trials found

federico, cammertoni

No trials found

Maccauro, Giulio

No trials found

Vitiello, Raffaele

No trials found



	Diseases Companies Products Productz Mechanisms of Action Sites